Physician profile
Benjamin R Cook
NPI 1679998975
$10,340.26
in general payments reported to CMS, 2019-2025
58 companies · $2,211 in 2025
The $2,211 reported for 2025 was more than what 96% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,140 · 2020: $312 · 2021: $1,058 · 2022: $1,782 · 2023: $1,776 · 2024: $2,062 · 2025: $2,211.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,049.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,048.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,723.54 | 2021-2025 | Qulipta, Ubrelvy, Vraylar |
| Pfizer INC. | $1,378.01 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $928.90 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Lilly USA, LLC | $819.56 | 2019-2025 | Mounjaro, Zepbound, Emgality |
| Amgen INC. | $812.24 | 2019-2025 | Repatha, Otezla, Otezla |
| Novo Nordisk INC | $655.79 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Jazz Pharmaceuticals INC. | $283.35 | 2021-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $278.78 | 2019-2025 | Jardiance |
| Abbott Laboratories | $257.64 | 2022-2025 | Freestyle Libre 3 |
| Takeda Pharmaceuticals U.S.A., INC. | $256.51 | 2019-2025 | Trintellix |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $213.87 | 2022-2025 | Caplyta |
| Glaxosmithkline, LLC. | $213.62 | 2019-2024 | Shingrix, Arexvy, Bexsero |
| Astellas Pharma US INC | $204.67 | 2019-2023 | Veozah |
| Teva Pharmaceuticals USA, INC. | $164.94 | 2020-2024 | Austedo Xr, Austedo |
| Biohaven Pharmaceutical Holding Company LTD. | $142.18 | 2022 |
Show all 56 companies
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Cook listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.